Dianthus
DNTH
Dianthus (DNTH) news
Recent news
Dianthus Therapeutics Inc: Raymond James raises target price to $131 from $125
AInvest Wire · Aug 5, 2026Dianthus Therapeutics - reports $1.20 bln cash as of June 30, 2026, provides expected runway into 2030
AInvest Wire · Aug 4, 2026Dianthus Therapeutics - DNT H312 expected to be Phase 1 ready by year-end 2027
AInvest Wire · Aug 4, 2026Dianthus Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) has announced the issuance of equity awards to newly hired non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4). On July 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 58,000 shares of its common…
AInvest Wire · Aug 3, 2026Dianthus Therapeutics - expects Phase 2 Momentum trial top-line data in Q4 2026 and Captivate update by YE 2026
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.